A Somatic MAP3K3 Mutation Is Associated with Verrucous Venous Malformation  by Couto, Javier A. et al.
REPORT
A Somatic MAP3K3 Mutation Is Associated
with Verrucous Venous Malformation
Javier A. Couto,1 Matthew P. Vivero,1 Harry P.W. Kozakewich,2,3 Amir H. Taghinia,1,2
John B. Mulliken,1,2 Matthew L. Warman,2,4,5,6 and Arin K. Greene1,2,*
Verrucous venous malformation (VVM), also called ‘‘verrucous hemangioma,’’ is a non-hereditary, congenital, vascular anomaly
comprised of aberrant clusters of malformed dermal venule-like channels underlying hyperkeratotic skin. We tested the hypothesis
that VVM lesions arise as a consequence of a somatic mutation. We performed whole-exome sequencing (WES) on VVM tissue from
six unrelated individuals and looked for somatic mutations affecting the same gene in specimens from multiple persons. We observed
mosaicism for a missense mutation (NM_002401.3, c.1323C>G; NP_002392, p.Iso441Met) in mitogen-activated protein kinase kinase
kinase 3 (MAP3K3) in three of six individuals. We confirmed the presence of this mutation via droplet digital PCR (ddPCR) in the three
subjects and found the mutation in three additional specimens from another four participants. Mutant allele frequencies ranged from
6% to 19% in affected tissue. We did not observe this mutant allele in unaffected tissue or in affected tissue from individuals with other
types of vascular anomalies. Studies using global and conditional Map3k3 knockout mice have previously implicated MAP3K3 in
vascular development. MAP3K3 dysfunction probably causes VVM in humans.Verrucous venous malformation (VVM) is a non-hereditary
vascular anomaly that is most commonly referred to as
verrucous ‘‘hemangioma’’ in the literature.1–5 VVMs occur
equally in males and females. The typical VVM lesion is
raised, reddish-purple, hyperkeratotic, and extends into
the subcutis. VVMs can be single or multiple (Figure 1).
91% of lesions occur in an extremity (usually legs) and 9%
involve the trunk.4 Other developmental anomalies have
not been reported in persons with VVM. Over time, a VVM
lesionmight slowly enlarge, become increasingly hyperker-
atotic, and exhibit more bleeding episodes. Histologically,
affected tissue contains clusters of venule-like channels
that immunostain positive for GLUT1 (Figure 2).4 VVMs
might represent another example of a genetic lethal
mutation that survives as a consequence of somatic mosai-
cism.6 Therefore, we looked for somatic mutations in VVM
lesions via whole-exome sequencing (WES).
The Committee on Clinical Investigation at Boston
Children’s Hospital approved this study, and informed
consent was obtained. VVM tissue specimens were
collected from individuals undergoing a clinically indi-
cated surgical resection. VVM was diagnosed based on his-
tory, physical examination, and histopathology. Genomic
DNAwas extracted from frozen specimens via the QIAamp
DNAMini kit (QIAGEN). Participant-specific indexed DNA
libraries were made as previously described7 and enriched
for exonic sequences via the SureSelect Human All Exon
V5 kit (Agilent Technologies). We generated R50 million
100-basepair paired-end reads for each DNA library
by using the Illumina HiSeq 2500 platform. WES data
analysis was performed as previously described,8 with addi-
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Novobarcode (Novocraft Technologies) and aligned to
the reference genome (UCSC hg19) by BWA.10 PCR
duplicates were removed for each WES dataset via Picard
MarkDuplicates. Reads around known insertions and
deletions in the genome were re-aligned with GATK soft-
ware.9,11 Comprehensive variant lists for each sample
were populated with VarScan2 software.12 Variants were
annotated with ANNOVAR software.13
For the six samples, we averaged 1083–2993 coverage
across the exome; we obtainedR303 coverage andR603
coverage for 80%–95% and 52%–88% of the exome,
respectively (Figure 3). We began filtering the data via
several criteria (Table 1). First, we considered only variants
that were present in R3 independent reads at loci
havingR303 coverage.We did this to reduce false-positive
results that can be caused by library preparation, sequenc-
ing error, or mismapping. Second, we removed synony-
mous variants and variants outside of coding regions
and splice sites. Third, we removed variants that were
present in dbSNP (build 138),14 the Exome Variant Server
(ESP6500), and/or the 1000 Genomes Project15 datasets,
because they probably represent heritable alleles. Fourth,
we further reduced the number of variants under consider-
ation by requiring R5 variant reads and by removing
variants that exhibited complete strand bias (i.e., only
sequence in one direction produced a variant read). Fifth,
we excluded variants found in >40% of the reads assum-
ing these too were probably inherited alleles. Sixth, we
focused on specific variants or on genes that contained a
different variant in R2 and then R3 specimens. A total
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Figure 1. Photographs of Lower and
Upper Extremities of Four Participants
whose Verrucous Venous Malformations
Contain a Somatic Mosaic MAP3K3
Missense Mutation
Shown are participant 4, age 13 years (A);
participant 6, age 19 years (B); participant
8, age 9 years (C); and participant 9, age
16 years (D).KRTAP1-1 (MIM 608819), MAP3K3 (MIM 602539), MUC2
(MIM 158370), MUC6 (MIM 158374), PHGR1, PRSS3
(MIM 613578), RHPN2, RP1L1 (MIM 608581), RPTN (MIM
613259), SPATA3, TMEM163, and ZNF141 (MIM 194648),
remained after filtering (Table 1).
We visually examined and compared variants in each of
the 14 candidates with other WES datasets by using Inte-
grative Genomics Viewer.16 Visual examination enabled
us to exclude 13 of 14 genes as representing sequencing
or mapping artifact, because these variants were also seen
in WES data from non-VVM samples. In contrast, we
observed a MAP3K3 missense variant (RefSeq accession
number NM_002401.3, c.1323C>G; RefSeq NP_002392,
p.Iso441Met) in three of six VVM samples and in no other
sample (Figure 3). This finding, coupled with published
data implicating mouse Map3k3 in endothelial cell differ-
entiation,17,18 led us to explore this mutation in greater
depth.The American Journal of HumanWe validated the presence of the
mutant MAP3K3 allele by PCR ampli-
fying the implicated sequence from
newly extracted affected tissue DNAfrom one participant who had the variant allele in
29/477 WES reads (~6% mutant allele frequency). Sanger
sequencing of 48 different PCR-amplimer-subclones
detected the mutant allele in three clones (~6% mutant
allele frequency). To screen for this mutation more effi-
ciently, we developed a droplet digital PCR (ddPCR)
assay19 with forward (50-TGCAGTACTATGGCTGTCTG-30)
and reverse (50-GTCTCACATGCATTCAAGG-30) primers
and with fluorescent reference (50-HEX-CCTGACCATcTTC
ATGGAGTACA-IBlk-30) and mutant allele (50-FAM-CC
TGACCATgTTCATGGAGTACA-IBlk-30) probes (Integrated
DNA Technologies). Approximately 30 ng of template
DNAwere used in each reaction. To validate the sensitivity
of our ddPCR assay, we serially diluted genomic DNA
that contained the mutant allele with wild-type genomic
DNA. The ddPCR detected a mutant allele frequency as
low as 1 mutant per 1,693 total alleles (data not shown).
We also determined whether ddPCR yielded the sameFigure 2. Photograph and Photomicro-
graphs of the Verrucous Venous Malfor-
mation from Participant 5
(A) VVM lesion that contains the somatic
mosaic MAP3K3 missense mutation.
(B) Hematoxylin-and-eosin-stained sec-
tion of the excised VVM. Note hyperkera-
tosis (asterisk), papillomatous epidermis
(arrow), and vascular clusters (arrowheads
and boxed area) within the papillary
dermis and reticular dermis, respectively,
that extend into subcutaneous fat.
(C) Higher-magnification photomicro-
graph of the boxed area in (B) showing a
cluster of venule-like channels.
(D) Immunostaining revealing GLUT1 ex-
pression in many endothelial cells within
the VVM lesion (arrows).
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Figure 3. Whole-Exome Sequencing of VVM DNA and Identification of a MAP3K3 Somatic Missense Mutation
(A) Bar graph indicating fold coverages across the exome for the VVM specimens subjected toWES. Specimens from participants 1 and 6
yieldedR903 coverage for ~80% of the exome.
(B) Portion of an Integrative Genomic Viewer screen shot depictingWES coverage at the site of the somatic missense mutation in partic-
ipant 6. The bar graph indicates the depth of coverage in the interval, which peaked at 5063. Coloring at the site of the mutation
indicates the relative proportions of reference (blue) and variant (orange) alleles in the sample. Examples of individual sequencing reads
(horizontal gray bars) containing the variant and reference allele are depicted below. Note that the 29 sequencing reads that contain the
variant (G) allele are in both directions and have no other variant residues indicative of poor sequence quality or mismapping.mutant allele frequencies as WES by using the WES
libraries as template in the ddPCR assay (data not shown);
there was no statistically significant difference in allele
frequencies determined by WES and ddPCR (Table 2 and
data not shown).
In addition to studying DNA from the first six VVM
samples, we analyzed four additional VVM DNA samples
from other participants by ddPCR (one frozen tissue, three
formalin-fixed paraffin-embedded tissues). We also studied
DNA that had been extracted from the skin of healthy
individuals (n ¼ 3) and from affected tissues from individ-
uals with other vascular anomalies (infantile hemangioma
[n ¼ 3], capillary malformation [n ¼ 3], venous malforma-
tion [n ¼ 3], lymphatic malformation [n ¼ 3], arteriove-
nous malformation [n ¼ 3]). With the ddPCR assay, we482 The American Journal of Human Genetics 96, 480–486, March 5confirmed that the MAP3K3 mutation was present in the
three VVM specimens where it had been initially found
by WES and in three of four new VVM specimens. The
mutant allele frequencies in the six VVM tissues in which
themutation was detected ranged from 6% to 19% (Table 2
and Figure 4). We did not detect the mutant allele in
healthy skin or affected tissue from individuals with other
vascular anomalies (data not shown). Also, we did not
detect the mutant allele in saliva DNA from four VVM
participants who had the mutant allele in their affected
tissue (Table 2).
With evidence that a specific somatic MAP3K3missense
variant (c.1323C>G [p.Iso441Met]) is present in six of
ten VVMs, we reviewed MAP3K3 WES data in the three
specimens that did not have this mutation. The average, 2015
Table 1. Variant Filtering for Six VVMs Subjected to Whole-Exome Sequencing
Participant Specimen
1 2 3 4 5 6
Minimum of 303 coverage and R3 variant reads 106,199 51,833 60,642 50,903 68,503 86,968
Considering only nonsynonymous variants 13,222 9,986 11,148 10,092 11,823 10,932
After excluding common variants (SNVs/indels) 1,600
(1,183/417)
1,846
(1,576/270)
2,597
(2,287/310)
1,911
(1,609/302)
2,609
(2,251/358)
1,540
(1,202/338)
After excluding SNVs with %5 variant reads 775 238 410 231 566 701
After excluding SNVs exhibiting strand bias 194 96 131 83 142 119
After excluding SNVs with allele
frequencies R40%
87 45 74 39 78 55
Genes having variants in R2 specimens
30
Genes having variants in R3 specimens 14: EPPK1, IGFN1, KRTAP1-1, MAP3K3, MUC2, MUC6, PHGR1, PRSS3, RHPN2, RP1L1,
RPTN, SPATA3, TMEM163, ZNF141
Abbreviations are as follows: indel, insertions and deletions; SNV, single-nucleotide variant.WES coverage across MAP3K3 in these specimens ranged
from 683 to 1873, and in one VVM sample the entire
MAP3K3 coding sequence was covered atR1003 coverage.
We did not find a suspicious MAP3K3 mutation (i.e., R3
variant reads) in any of these three specimens. It remains
possible that the specimens have mutant MAP3K3 alleles,
but at frequencies too low to detect. Alternatively,
VVM might also be associated with somatic mutation
affecting another gene. Although all ten specimens
were typical of VVM, there exists similarity betweenTable 2. MAP3K3 Mutation Detection in Ten Participants Affected wi
Participant Age Sex Location DNA So
1 9 months M leg frozen
2 1 year F arm frozen
3 3 years M trunk frozen
4 13 years F leg frozen
saliva
5 18 years F leg frozen
saliva
6 19 years M leg frozen
7 2 years M arm FFPE
8 9 years F arm FFPE
saliva
9 16 years F leg FFPE
saliva
10 23 years F leg FFPE
aMutant reads/total reads (mutant allele percentage). – indicates test not perform
bMutant droplets/wild-type droplets (mutant allele percentage calculation co
amplimers).
cThe mutant allele frequency determined by ddPCR using the same template DN
The AmeVVM and other vascular malformations, including angio-
keratoma, capillary-lymphatic malformation, cutaneous
lesions associated with cerebral cavernous malformations
(CCM [MIM 116860]), and glomuvenous malformation
(GVM [MIM 138000]). Therefore, we examined WES
data, but did not find evidence for mutation in PIK3CA
(MIM 171834), TIE2 (TEK [MIM 600221]), GLMN (MIM
601749), KRIT1 (MIM 604214), CCM2 (MIM 607929), or
PDCD10 (MIM 609118), which are the genes responsible
for these other disorders.20,21th VVM
urce Whole-Exome Sequencinga ddPCRb
0/539 (0%) 0/3,973 (0%)
0/176 (0%) 0/1,298 (0%)
0/228 (0%) 0/3,826 (0%)
13/167 (7.8%)c 347/2,627 (10.7%)
– 0/3,394 (0%)
13/253 (5.1%)c 239/3,675 (5.5%)
– 0/3,241 (0%)
29/477 (6.1%)c 431/3,834 (9.1%)
– 248/1,228 (16.3%)
– 247/1,016 (19.3%)
– 0/2,428 (0%)
– 207/2,946 (6.1%)
– 0/4,261 (0%)
– 0/2,053 (0%)
ed.
nsiders droplets containing mutant, mutant and wild-type, and wild-type
A is not statistically different from the frequency determined by WES.
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Figure 4. Representative Results for the MAP3K3 c.1323C>G Mutation ddPCR Assay
(A) Graph depicting the amplitudes of FAM fluorescence droplets (blue dots) containing mutant alleles (y axis) and HEX fluorescence
droplets (green dots) containing wild-type alleles (x axis) from a ddPCR reaction performed with VVM DNA as template. Cross-hairs
indicate the fluorescence cutoffs that we used to call a droplet positive for a wild-type or mutant allele. Note the presence of mutant
allele containing droplets in this sample. Some droplets contain mutant and wild-type amplimers (orange dots). The numbers of empty,
mutant, mutant and wild-type, and wild-type amplimer containing droplets in this reaction are 12,987, 406, 129, and 4,323,
respectively.
(B and C) Similar graphs for ddPCR reactions performed with DNA from infantile hemangioma (B) and venous malformation (C) spec-
imens as template. Note the absence of mutant amplimer containing droplets in each of these two reactions.
(D) Results from a ddPCR reaction performed with no template DNA. All droplets are negative for wild-type and mutant DNA amplimer.Our data strongly support a somatic missense mutation
in MAP3K3 as a cause of VVM. The isoleucine residue
(Iso441) is fully conserved across evolution. MAP3K3 is
one of 21 members of the MAP kinase kinase kinase
(MAP3K) family of serine/threonine phosphorylases.22
Studies on mice with global and conditional knockout
alleles of Map3k3 have previously implicated this gene in
vascular development. Mice lackingMAP3K3 die at embry-
onic day 10.5 because of abnormalities in extra-embryonic
vasculature of the yolk sac, the embryonic vasculature, and
the heart.18 Conditional ablation of Map3k3 placed it
downstream of the angiopoietin-1 (ANG1) and tyrosine
kinase with immunoglobulin and EFG-like domains-2
(TIE2) signaling pathway.17 TIE2 is a known vascular mal-
formation locus, with gain-of-function mutations segre-
gating in families with dominant venous malformation
phenotypes23 and somatic gain-of-function mutations de-
tected in sporadically occurring venous malformations.24
Because mice lacking one copy of Map3k3 do not develop484 The American Journal of Human Genetics 96, 480–486, March 5vascular malformations and mice lacking two copies fail
to form vasculature, it seems likely that the somatic
mutation we identified in MAP3K3 creates a neomorphic
or hypermorphic function.
Imperial and Helwig1 suggested that VVM was a
‘‘vascular malformation,’’ but instead labeled the lesion
‘‘verrucous hemangioma’’ probably because, at that time,
most vascular anomalies were called hemangioma.25,26
We have preferred the term verrucous venous malfor-
mation for this lesion because it most closely resembles a
hyperkeratotic venous malformation based on its clinical,
radiologic, and pathologic features.27,28 Our finding that
VVM contains a MAP3K3 mutation supports our impres-
sion that this lesion is a venous anomaly. No somatic
mutation affecting Iso441 has been reported in COSMIC,
the catalog of somatic mutation in cancer,29 which is
also consistent with VVM being a malformation rather
than a tumor. Identifying molecular etiologies for VVM
should facilitate the search for better therapies., 2015
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